Heterogeneity of CLL: high CD23 antigen and αIFN receptor expression are features of favourable disease and of cell activation
- 12 March 1988
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 68 (3) , 279-282
- https://doi.org/10.1111/j.1365-2141.1988.tb04203.x
Abstract
Summary The relationship between α‐interferon receptor (αIFNR) numbers, B‐cell‐antigen expression and clinical stage was determined in 35 cases of typical chronic lymphocytic leukaemia (CLL). αIFNR numbers were shown to be low in patients with advanced disease and high in those with a more favourable prognosis. The B‐cell activation antigen CD 23 was similarly related to stage, being high in more favourable disease. Also, αIFNR expression was directly related to CD 23 positivity, but αIFN binding was not inhibited by CD 23 monoclonal antibody. There was no correlation between CD 19, 20, 22 and 24 antigen expression and either αIFNR numbers or clinical stage.Since CD23 antigen expression is a feature of B‐cell activation, we suggest that high CD23 and αIFNR positivity are manifestations of an activated cell phenotype and that cell activation in CLL is a feature of favourable disease.This publication has 15 references indexed in Scilit:
- Long survival in B-CLL correlates with surface IgMKphenotypeBritish Journal of Haematology, 1987
- Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia‐a pilot studyAmerican Journal of Hematology, 1987
- Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study.Journal of Clinical Oncology, 1986
- The mechanism of action of interferon-α (IFN-α) in hairy-cell leukaemia; Hu-IFN-α2 receptor expression by hairy cells and other normal and leukaemic cell typesLeukemia Research, 1986
- BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus.The Journal of Immunology, 1985
- Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemiaThe American Journal of Medicine, 1985
- An indirect rosette technique for the identification and separation of human lymphocyte populations by monoclonal antibodies: A comparison with immunofImmunology Letters, 1983
- A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisCancer, 1981
- A hemalog D analysis of chronic lymphocytic leukaemia and other lymphoproliferative disorders affecting the blood.Journal of Clinical Pathology, 1981
- Clinical staging of chronic lymphocytic leukemiaBlood, 1975